(Bloomberg) — Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion.The cash and stock agreement will bring closely held Thrive’s CancerSeek technology to Exact Sciences, helping establish the Madison, Wisconsin-based company as a competitor in blood-based, multi-cancer screening, according to a statement. Exact Sciences jumped as much as 22% to $130, its highest since the shares began trading in 2001.Testing companies are increasingly developing liquid biopsies that sift through patients’ blood for early signs of tumors, hoping to help doctors begin treatment before …read more
Source:: Yahoo Finance
